|
Competency A: What is the scientific and clinical context of the study? |
|
Subcompetency |
Justification |
Data Requirement |
|
1. What is the disease or problem being studied? |
Requires definition of the disease or problem under study |
a. definition of disease or problem |
|
2. What is the importance of the disease or problem being studied? |
What are the clinical implications of this disease or problem? |
a. i. mortality and ii. morbidity of this disease |
|
A disease or problem that affects many new people each year is more important |
b. incidence in different racial, gender, socioeconomic groups |
|
The prevelance of a disease or problem speaks to its ongoing burden, and consequently
its importance |
c. prevalence in different racial, gender, socioeconomic groups |
|
The socioeconomic impact of the disease under study is important for policy decisions |
d. monetary cost of treating this disease |
|
3. What is the postulated pathophysiology or etiology of the problem? |
Pathophysiologic context for interpretation of mechanism and efficacy |
a. disease hypotheses |
|
Is the hypothesized effect biologically plausible? |
b. postulated mechanism behind each hypothesis |
|
Supporting evidence, especially from humans, helps to evaluate the truth of the hypotheses |
c. i. animal and ii. human study evidence behind each hypothesis |
|
4. What was the authors' statement of clinical application? |
The authors' clinical recommendation is the one that many readers key in on |
a. authors' statement of clinical application |
|
5. Is there post-trial follow-up (e.g. post-marketing studies) available? |
Long-term follow-up data after official trial close-out is important for detecting rare events |
a. post-marketing studies |
|
Competency B: What is the scientific discourse on the study question? |
|
Subcompetency |
Justification |
Data Requirement |
|
1. In what venues was this trial information disseminated? |
Different publishing sources espouse different peer review standards and may promote particular biases (e.g. commercial or specialty biases) |
a.trial publications i. title, ii. journal, iii. volume, iv. no, v. pages, vi. year, vii. peer-review status |
|
2. What is the current or anticipated information from other relevant studies?
|
Reflects upcoming trends, research questions, etc. |
a. planned trials
|
|
Trials that are ongoing may resolve outstanding questions |
b. ongoing related trials |
|
Other relevant completed studies are part of the scientific context |
c. other primary and secondary research in the literature |
|
General commentary on the study question provides additional context. |
d. editorials, other commentary on study question |
|
3. How have the results of this study been synthesized with other evidence? |
Best approach to finding the scientific context of the trial |
a. systematic reviews that include this trial |
|
Formal frameworks for incorporating costs, societal tradeoffs, and patient preferences into interpretation of trial results |
b. decision analyses/cost-effectiveness analyses that include this trial |
|
Synthesizes information from trial into action for clinicians |
c. practice guidelines that include this trial |
|
Reflects non-systematic, and therefore possibly biased, commentary on related subjects |
d. non-systematic reviews that cite this trial |
|
4. What is the commentary on this trial? |
Reflects opinions of peers |
a. letters to the editor |
|
Reflects opinions of anointed, usually expert, commentator |
b. editorials |
|
Reflects opinions of others in addition to above |
c. consumer articles, press releases, bulletin boards, discussion groups that cite this trial |
|
Competency C: What is the social, economic, and ethical context of this study? |
|
Subcompetency |
Justification |
Data Requirement |
|
1. Was the trial conducted ethically? |
Human Subjects Committees (i.e., Institutional Review Boards) are a committee of peers charged with ensuring human rights compliance of study design |
a. whether Human Subjects Committee approval i. sought, and ii. granted |
|
By Geneva human-rights convention, subjects must be informed of risks of study, and must give informed consent |
b. whether informed consent obtained from all subjects |
|
Method may reveal undue pressuring of subjects to give informed consent |
c. method for obtaining informed consent |
|
Patient data collected in course of trial should be kept confidential and non-identifiable |
d. method for protecting patient confidentiality |
|
The presence of subject representatives on a study monitoring committee increases likelihood of the trial conduct being sensitive to patient concerns |
e. whether subject representatives participated in study monitoring committee |
|
2. Is this trial a pivotal trial for product approval? |
Pivotal trials provide critical support for bringing intervention to market |
a. FDA filings including this trial |
|
3. Was the publication of the study influenced by outside events? |
Outside motives for releasing data, e.g. stock price, may introduce bias |
a. why study published when it was |
|
Events around time of publication may have influenced reporting |
b. submission and publication date |